Cervical intraepithelial neoplasia

Nutcracker Therapeutics Demonstrates Enhanced Functional Activity of Prostate Cancer Candidate NTX-470 at the 2024 AACR Annual Meeting

Retrieved on: 
Thursday, April 11, 2024
Software, Research, Men, Pharmaceutical, Oncology, Consumer, Technology, Genetics, Clinical Trials, Science, Biotechnology, Health, PSMA, CD3, University, WT, STEAP1, RNA, Tumor microenvironment, Protein engineering, Prostate cancer, Engineering, HVEM, Patient, Cervical intraepithelial neoplasia, Toxicity, Messenger, Beauty, AACR, Therapy, Vaccine

Of these, NTX-470 showed the strongest target cell killing activity – it was capable of engaging CD3 T cells, while displaying minimal activity in the absence of STEAP1- or PSMA-expressing target cells, retaining low bystander activity.

Key Points: 
  • Of these, NTX-470 showed the strongest target cell killing activity – it was capable of engaging CD3 T cells, while displaying minimal activity in the absence of STEAP1- or PSMA-expressing target cells, retaining low bystander activity.
  • LIGHT comes in two forms: membrane-bound or soluble, with the former generally having stronger activity, leading to the hypothesis that limiting membrane shedding would enhance advantageous activity.
  • Nutcracker’s scientists engineered multiple variants of LIGHT with either flexible or rigid linkers in place of protease-sensitive sites, to explore how membrane shedding susceptibility affects immunomodulatory activity.
  • Of the tested designs, membrane-stabilized variants of LIGHT enhanced HVEM stimulation over WT LIGHT and increased proinflammatory cytokines in the tumor microenvironment.

Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Hypersensitivity, Pregnancy, Wart, Head, Congress, Recombinant, Multiple endocrine neoplasia, Dizziness, Safety, Vain, Headache, Bruise, Public, Syncope, Ageing, Merck & Co., Cervical intraepithelial neoplasia, Vulvar intraepithelial neoplasia, Anal cancer, Virus-like particle, Observation, CIN, Thigh, Human, HPV, Plant, Vaginal intraepithelial neoplasia, Nausea, MRK, VLP, Investment, Immunity, Fever, Erythema, Vaccination, Injury, Vaccine, Allergy, Itch, AIN, Swelling

Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.

Key Points: 
  • Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • The latest addition to the pipeline employs the company’s proprietary virus-like particle (VLP) technology to incorporate additional VLPs for expanded HPV type coverage.
  • These randomized, double-blind, multi-year clinical trials will examine the short and long-term efficacy and immunogenicity of a single-dose of GARDASIL 9 versus the currently approved three-dose regimen.

Nutcracker Therapeutics to Present Data on mRNA Drug Candidate and Immunomodulatory Cytokine at AACR 2024

Retrieved on: 
Tuesday, March 12, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Online, Toxicity, Nutcracker, Prostate cancer, RNA, Cervical intraepithelial neoplasia, Abstract, AACR, Therapy, Antigen

The first presentation entails LIGHT, an immunomodulatory cytokine that is one of the components of NTX-250, the company’s lead candidate for cervical intraepithelial neoplasia.

Key Points: 
  • The first presentation entails LIGHT, an immunomodulatory cytokine that is one of the components of NTX-250, the company’s lead candidate for cervical intraepithelial neoplasia.
  • The second presentation is on preclinical data for Nutcracker’s mRNA drug candidate for prostate cancer, NTX-470.
  • This therapy is designed to target prostate cancer antigens with mRNA-encoded, multi-specific T cell engagers with a strong anti-tumor effect and low toxicity.
  • The 2024 AACR Annual Meeting takes place in San Diego from April 5-10.

Nutcracker Therapeutics Demonstrates Anti-tumor Responses of Two Preclinical mRNA Drug Candidates at 2023 SITC Annual Meeting

Retrieved on: 
Tuesday, November 7, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Neoplasm, Human papillomavirus infection, Cervical cancer, Mouse, Anemia, CIN, Therapy, RNA, HPV, Cervical intraepithelial neoplasia, CD47, Immortalised cell line, Cell, Protein, Engineering, SITC, Immunotherapy, HPV16, Messenger, Animal, Society, Alpha globulin, Patient, Vivo, Vaccine, Nutcracker

These data were presented at the Society for Immunotherapy of Cancer’s (SITC’s) 38th Annual Meeting.

Key Points: 
  • These data were presented at the Society for Immunotherapy of Cancer’s (SITC’s) 38th Annual Meeting.
  • Anemia is the most common adverse effect of CD47-targeting molecules, since red blood cells also express CD47.
  • Moreover, modifying the RNA sequence of the prospective anti-CD47 molecule is far more efficient than engineering the final protein product.
  • Our platform has made it possible for Nutcracker to lay a strong and early foundation for our future therapeutic work.”

Daré Bioscience Completes Previously Announced Equity Financing

Retrieved on: 
Tuesday, September 5, 2023
Cream, Vulvectomy, Diclofenac, Woman, Trial of the century, Douglas Pharmaceuticals, Pain, Human papillomavirus infection, SAN, HPV, FDA, Cervical intraepithelial neoplasia, Organon, Female, Birth control

The aggregate gross proceeds to Daré, before deducting offering expenses payable by Daré, were $7.0 million.

Key Points: 
  • The aggregate gross proceeds to Daré, before deducting offering expenses payable by Daré, were $7.0 million.
  • The closing occurred on September 1, 2023.
  • “This financing strengthened our balance sheet, providing cash to help us deliver on important portfolio milestones this year,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
  • A pharmaceutical approach could provide women with an important alternative to surgery to treat this condition.”
    Daré’s completed equity financing included minority participation by an investor affiliated with Douglas.

Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL®9 Published in Pediatrics

Retrieved on: 
Tuesday, September 5, 2023
Research, Teens, Infectious Diseases, Children, Clinical Trials, Biotechnology, Pharmaceutical, Consumer, Health, Science, MSD, Hypersensitivity, CIN, Male, Female, Pediatrics, Allergy, Life, Vaccination, CIN1, Human papillomavirus infection, Cancer, MRK, Vulvar cancer, Woman, Head, Month, AIS, Vulvectomy, Merck & Co., CDC, Incidence, Death, PIN, Anal cancer, Cervical cancer, Wart, Vain, Vaginal intraepithelial neoplasia, HPV, VIN, Cervical intraepithelial neoplasia, Anus, NYSE, Disease, Vaccine, Birth control, Recombinant, Merck

The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease.

Key Points: 
  • The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • As part of the primary objective of immunogenicity, data showed sustained HPV-antibody responses at 10 years after the third dose in boys and girls.
  • With the exception of cervical cancer, there is no routinely recommended screening for the detection of HPV-related cancers.

Cervical Intraepithelial Neoplasia Drug Pipeline Research Report 2023 Featuring Inovio Pharmaceuticals, Frantz Viral Therapeutics, Antiva Biosciences, Genexine, and Merck Sharp & Dohme - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 20, 2023
Health, Pharmaceutical, CIN, Artesunate, Society, Therapy, Clinical trial, NDA, Woman, Society of Gynecologic Oncology, Cervical intraepithelial neoplasia, Research, Candidiasis, E7, Discovery, E6, Gynaecology, HPV, Growth, Intraepithelial neoplasia, III, Inovio Pharmaceuticals, Human papillomavirus infection, News, Birth control, Pharmaceutical industry, Gynecologic Oncology (journal), Cervical, Phase

The "Cervical Intraepithelial Neoplasia - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Intraepithelial Neoplasia - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This report report offers a comprehensive analysis of the current landscape and future growth prospects in the field of Cervical Intraepithelial Neoplasia.
  • This report provides a detailed overview of the pipeline for Cervical Intraepithelial Neoplasia, including profiles of over 8 companies and 10 pipeline drugs.
  • The companies which have their Cervical Intraepithelial Neoplasia drug candidates in the most advanced stage, i.e.

Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate at the 2023 AACR Annual Meeting

Retrieved on: 
Wednesday, April 19, 2023
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, CIN, AACR, CD1D, University, HPV16, RNA, Messenger, E7, Cervical cancer, Patient, Antigen presentation, Nutcracker, HPV, Neoplasm, Cervical intraepithelial neoplasia, Therapy, Tumor microenvironment, Human papillomavirus infection, Prostate cancer, Pharmaceutical industry, Vaccine, DRS

Nutcracker Therapeutics , Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today presented two posters showcasing the latest preclinical data for the company’s lead oncology mRNA therapeutic, NTX-250, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Fla. (April 14-19).

Key Points: 
  • Nutcracker Therapeutics , Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today presented two posters showcasing the latest preclinical data for the company’s lead oncology mRNA therapeutic, NTX-250, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Fla. (April 14-19).
  • The lead indication for NTX-250 is cervical intraepithelial neoplasia (CIN), a precancerous condition caused by human papillomavirus (HPV) infection, which can progress to cervical cancer if left untreated.
  • More than 90 percent of cervical cancer and CIN cases are linked to HPV infection, with HPV16 as the most prevalent high-risk strain.
  • Lawrence Fong and David Oh at the University of California, San Francisco — which mapped shared tumor antigen reactivity using nanoparticle-encapsulated mRNA in prostate cancer patients.

Cervical Dysplasia Market is expected to generate a revenue of USD 789.32 Million by 2030, Globally, at 7% CAGR: Verified Market Research®

Retrieved on: 
Monday, January 30, 2023
Conditional sentence, Dickinson, USD, Quest Diagnostics, Diagnosis, Midsayap Diagnostic Center and Hospital, Vulvectomy, Cervical intraepithelial neoplasia, Government, Minerva Surgical, Inc. v. Hologic, Inc., Drug combination, Woman, QIAGEN, Cancer, Geography, Cervical cancer, Hospital, Mortality, Test management, Research, Projection, Retail, Medical device, Birth control

JERSEY CITY, N.J. , Jan. 30, 2023 /PRNewswire/ -- Verified Market Research® recently published a report, "Cervical Dysplasia Market" By Diagnostic (Diagnostic Tests, Diagnostic Devices), By End-User (Hospitals, Diagnostic Centers), and By Geography.

Key Points: 
  • JERSEY CITY, N.J. , Jan. 30, 2023 /PRNewswire/ -- Verified Market Research® recently published a report, " Cervical Dysplasia Market " By Diagnostic (Diagnostic Tests, Diagnostic Devices), By End-User (Hospitals, Diagnostic Centers), and By Geography.
  • The "Global Cervical Dysplasia Market" is mainly bifurcated into sub-segments which can provide classified data regarding the latest trends in the market.
  • The "Global Cervical Dysplasia Market" study report will provide valuable insight with an emphasis on the global market.
  • Ltd, OncoHealth Corporation, Inc., and Hologic, Inc.
    Based on the research, Verified Market Research® has segmented the global Cervical Dysplasia Market into Diagnostic, End-User, and Geography.

Cervical Dysplasia Market is expected to generate a revenue of USD 789.32 Million by 2030, Globally, at 7% CAGR: Verified Market Research®

Retrieved on: 
Monday, January 30, 2023
Conditional sentence, Dickinson, USD, Quest Diagnostics, Diagnosis, Midsayap Diagnostic Center and Hospital, Vulvectomy, Cervical intraepithelial neoplasia, Government, Minerva Surgical, Inc. v. Hologic, Inc., Drug combination, Woman, QIAGEN, Cancer, Geography, Cervical cancer, Hospital, Mortality, Test management, Research, Projection, Retail, Medical device, Birth control

JERSEY CITY, N.J., Jan. 30, 2023 /PRNewswire/ -- Verified Market Research® recently published a report, "Cervical Dysplasia Market" By Diagnostic (Diagnostic Tests, Diagnostic Devices), By End-User (Hospitals, Diagnostic Centers), and By Geography.

Key Points: 
  • JERSEY CITY, N.J., Jan. 30, 2023 /PRNewswire/ -- Verified Market Research® recently published a report, " Cervical Dysplasia Market " By Diagnostic (Diagnostic Tests, Diagnostic Devices), By End-User (Hospitals, Diagnostic Centers), and By Geography.
  • The "Global Cervical Dysplasia Market" is mainly bifurcated into sub-segments which can provide classified data regarding the latest trends in the market.
  • The "Global Cervical Dysplasia Market" study report will provide valuable insight with an emphasis on the global market.
  • Ltd, OncoHealth Corporation, Inc., and Hologic, Inc.
    Based on the research, Verified Market Research® has segmented the global Cervical Dysplasia Market into Diagnostic, End-User, and Geography.